Molecular Signatures of HNSCC in Response to Targeted Therapies
OBJECTIVES:
- To identify 100 patients from the Head and Neck Tumor Tissue Repository and Clinical
Database treated with cetuximab monotherapy or cetuximab-containing combination therapy
as a standard of care for recurrent and/or metastatic head and neck squamous cell
carcinoma at Vanderbilt University Medical Center.
- To assay the diversity of gene and protein expression patterns seen in these patients.
- To identify predictive patterns associated with treatment response and survival of
these patients by correlating the laboratory data with clinical data.
OUTLINE: Tumor tissue specimens and clinical data are obtained from the Head and Neck Tumor
Tissue Repository and Clinical Database protocol VU-VICC-HN-0356. Specimens are analyzed for
patterns of gene and protein expression predictive of cetuximab treatment response and
survival by DNA microarray, tissue microarray, reverse transcriptase-PCR, and mass
spectroscopy.
Observational
Observational Model: Case-Only, Time Perspective: Retrospective
Identification of 100 patients from the Head and Neck (H&N) Tumor Tissue Repository and Clinical Database treated with cetuximab or cetuximab-containing combination therapy as a standard of care
approximately three years from enrollment of first patient
No
Barbara Murphy, MD
Study Chair
Vanderbilt-Ingram Cancer Center
United States: Federal Government
VICC HN 0715
NCT00898742
April 2007
June 2010
Name | Location |
---|---|
Vanderbilt-Ingram Cancer Center | Nashville, Tennessee 37232-6838 |
Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville, Tennessee 37064 |
Vanderbilt-Ingram Cancer Center at Franklin | Nashville, Tennessee 37064 |